Belgium
ExeVir, founded in 2020, is a promising biotech startup headquartered in Ghent, Belgium. The company aims to revolutionize infectious disease treatment with its unique heavy chain-only antibodies. Emphasizing its slogan, “Rapid Viral control in a world that needs it,” ExeVir focuses on pandemic preparedness through its advanced technology platform utilizing humanized camelid VHH fragments.
Their principal innovation lies in designing cost-effective, stable mono-specific and multi-specific VHH-Fc constructs. These constructs offer superior combinatory flexibility and can access highly conserved epitopes typically unreachable by conventional monoclonal antibodies. ExeVir's leading compound, XVR013m, is tailored for protection and treatment of vulnerable populations, such as the immunocompromised and elderly.
Supported by Series A financing and bolstered by non-dilutive funding from VLAIO and Horizon, the company recently secured a €1.60M grant from Agentschap Innoveren & Ondernemen in June 2023. ExeVir is strategically positioned as a transformative force in life sciences, with a solid pipeline initially targeting COVID-19 and dengue.
